153 related articles for article (PubMed ID: 33552128)
1. Investigation on Potential Correlation Between Small Nuclear Ribonucleoprotein Polypeptide A and Lung Cancer.
Yuan M; Yu C; Chen X; Wu Y
Front Genet; 2020; 11():610704. PubMed ID: 33552128
[No Abstract] [Full Text] [Related]
2. Elevated Small Nuclear Ribonucleoprotein Polypeptide an Expression Correlated With Poor Prognosis and Immune Infiltrates in Patients With Hepatocellular Carcinoma.
Zhang Y; Wang X; Wang H; Jiang Y; Xu Z; Luo L
Front Oncol; 2022; 12():893107. PubMed ID: 35860579
[TBL] [Abstract][Full Text] [Related]
3. The Effect of GLUT1 on the Survival Rate and Immune Cell Infiltration of Lung Adenocarcinoma and Squamous Cell Carcinoma: A Meta and Bioinformatics Analysis.
Zhang G; Dong R; Kong D; Liu B; Zha Y; Luo M
Anticancer Agents Med Chem; 2022; 22(2):223-238. PubMed ID: 34238200
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of HOXA3 in lung adenocarcinoma and its relevant molecular mechanism analysed by RT-qPCR, TCGA and in silico analysis.
Gan BL; He RQ; Zhang Y; Wei DM; Hu XH; Chen G
Int J Oncol; 2018 Oct; 53(4):1557-1579. PubMed ID: 30066858
[TBL] [Abstract][Full Text] [Related]
5. High ECT2 expression is an independent prognostic factor for poor overall survival and recurrence-free survival in non-small cell lung adenocarcinoma.
Zhou S; Wang P; Su X; Chen J; Chen H; Yang H; Fang A; Xie L; Yao Y; Yang J
PLoS One; 2017; 12(10):e0187356. PubMed ID: 29088286
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of IL-6R mRNA in lung adenocarcinoma and squamous cell carcinoma.
Xu B; Chen Q; Yue C; Lan L; Jiang J; Shen Y; Lu B
Oncol Lett; 2018 Sep; 16(3):2935-2948. PubMed ID: 30127882
[TBL] [Abstract][Full Text] [Related]
7. Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma.
Xu XL; Gong Y; Zhao DP
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8731-8739. PubMed ID: 30575913
[TBL] [Abstract][Full Text] [Related]
8. Identification of the key genes and characterizations of Tumor Immune Microenvironment in Lung Adenocarcinoma (LUAD) and Lung Squamous Cell Carcinoma (LUSC).
Zhang L; Chen J; Cheng T; Yang H; Li H; Pan C
J Cancer; 2020; 11(17):4965-4979. PubMed ID: 32742444
[TBL] [Abstract][Full Text] [Related]
9. Exploring and comparing of the gene expression and methylation differences between lung adenocarcinoma and squamous cell carcinoma.
Yang Y; Wang M; Liu B
J Cell Physiol; 2019 Apr; 234(4):4454-4459. PubMed ID: 30317601
[TBL] [Abstract][Full Text] [Related]
10. Validation and analysis of expression, prognosis and immune infiltration of WNT gene family in non-small cell lung cancer.
Wang J; Yang Q; Tang M; Liu W
Front Oncol; 2022; 12():911316. PubMed ID: 35957916
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Profiling of Genomic and Transcriptomic Differences between Risk Groups of Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
Zengin T; Önal-Süzek T
J Pers Med; 2021 Feb; 11(2):. PubMed ID: 33672117
[TBL] [Abstract][Full Text] [Related]
12. Increased GOLM1 Expression Independently Predicts Unfavorable Overall Survival and Recurrence-Free Survival in Lung Adenocarcinoma.
Liu X; Chen L; Zhang T
Cancer Control; 2018; 25(1):1073274818778001. PubMed ID: 29843532
[TBL] [Abstract][Full Text] [Related]
13. LncRNAs are altered in lung squamous cell carcinoma and lung adenocarcinoma.
Liu B; Chen Y; Yang J
Oncotarget; 2017 Apr; 8(15):24275-24291. PubMed ID: 27903974
[TBL] [Abstract][Full Text] [Related]
14. High expression of SLC6A10P contributes to poor prognosis in lung adenocarcinoma.
Yuan K; Gao ZJ; Yuan WD; Yuan JQ; Wang Y
Int J Clin Exp Pathol; 2018; 11(2):720-726. PubMed ID: 31938158
[TBL] [Abstract][Full Text] [Related]
15. Integrative Multi-Omics Analysis of Identified NUF2 as a Candidate Oncogene Correlates With Poor Prognosis and Immune Infiltration in Non-Small Cell Lung Cancer.
Chen M; Li S; Liang Y; Zhang Y; Luo D; Wang W
Front Oncol; 2021; 11():656509. PubMed ID: 34178642
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer.
Larsen TV; Hussmann D; Nielsen AL
Cancer Commun (Lond); 2019 Jun; 39(1):30. PubMed ID: 31159869
[TBL] [Abstract][Full Text] [Related]
17. The value of CEP55 gene as a diagnostic biomarker and independent prognostic factor in LUAD and LUSC.
Fu L; Wang H; Wei D; Wang B; Zhang C; Zhu T; Ma Z; Li Z; Wu Y; Yu G
PLoS One; 2020; 15(5):e0233283. PubMed ID: 32437446
[TBL] [Abstract][Full Text] [Related]
18. Pyruvate kinase M2 is a marker of poor prognosis in lung adenocarcinoma but not lung squamous cell carcinoma.
Zhang J; Zhang C; Liu X; Sun N; Zhang C; Li R; Zhang Z
Transl Cancer Res; 2020 May; 9(5):3293-3302. PubMed ID: 35117696
[TBL] [Abstract][Full Text] [Related]
19. Skp2 expression has different clinicopathological and prognostic implications in lung adenocarcinoma and squamous cell carcinoma.
Zhong K; Yang F; Han Q; Chen J; Wang J
Oncol Lett; 2018 Sep; 16(3):2873-2880. PubMed ID: 30127874
[TBL] [Abstract][Full Text] [Related]
20. Identification of the prognostic and therapeutic values of cyclin E1 (
Ullah MA; Farzana M; Islam MS; Moni R; Zohora US; Rahman MS
Heliyon; 2022 Sep; 8(9):e10367. PubMed ID: 36091953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
